Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Next-generation antigen-presenting cell immune therapeutics for gliomas. [PDF]
J Clin Invest, 2023 Lee-Chang C, Lesniak MS.
europepmc +1 more source
Cancer vaccines: uses of HLA transgenic mice compared to genetically modified mice [PDF]
, 2008 Many tumor antigens have been identified that can be targeted by the immune system. Animal models that have been genetically modified to express human HLA molecules instead of their own MHC antigens have shown to be valuable in the discovery of peptides ...
McArdle, SE
core
Molecular Oncology, EarlyView.Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Antigen Presenting Cell-Mediated HIV-1 Trans Infection in the Establishment and Maintenance of the Viral Reservoir. [PDF]
Med Res Arch, 2023 Gerberick A, Rinaldo CR, Sluis-Cremer N.
europepmc +1 more source
Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. [PDF]
, 2009 Subcapsular sinus (SCS) macrophages capture antigens from lymph and present them intact for B cell encounter and follicular delivery. However, the properties of SCS macrophages are poorly defined.
Cyster, Jason G +4 more
core
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity
Molecular Oncology, EarlyView.Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek +2 more
wiley +1 more source
Comprehensive single-cell analysis reveals novel anergic antigen-presenting cell subtypes in human sepsis. [PDF]
Front Immunol, 2023 Zhang T +10 more
europepmc +1 more source
Protein O‐glycosylation in the Bacteroidota phylum
FEBS Open Bio, EarlyView.Species of the Bacteroidota phylum exhibit a unique O‐glycosylation system. It modifies noncytoplasmic proteins on a specific amino acid motif with a shared glycan core but a species‐specific outer glycan. A locus of multiple glycosyltransferases responsible for the synthesis of the outer glycan has been identified.
Lonneke Hoffmanns +2 more
wiley +1 more source
Immunostimulatory effects of marine algae extracts on in vitro antigen-presenting cell activation and in vivo immune cell recruitment. [PDF]
Food Sci Nutr, 2023 Ho TL +6 more
europepmc +1 more source